Decision to list continence products supplied by SPQ Limited
We are pleased to announce the approval of a non-exclusive listing agreement with SPQ Limited for the supply of continence products to DHBs.
What we’re doing
We are pleased to announce the approval of a non-exclusive listing agreement with SPQ Limited (“SPQ”) for the supply of continence products to DHBs.
In summary, this will result in:
- SPQ’s continence products being listed in Part III of Section H of the Pharmaceutical Schedule from 1 May 2019.
- DHBs continuing to be able to purchase other suppliers’ brands of continence products as the agreement is not for sole supply.
Any changes to the original proposals?
No changes have been made to the agreement as a result of the consultation feedback.
Who we think will be most interested
- Suppliers and Wholesalers
- DHB Staff
- clinical staff in a range of inpatient, outpatient and community settings where continence products are used
- procurement and supply chain personnel
Detail about this decision
The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After evaluating SPQ’s proposal, and consulting on the provisional agreement, PHARMAC has decided to list SPQ’s range of continence products in Part III of Section H of the Pharmaceutical Schedule, from 1 May 2019.
This agreement is the latest to arise from the urology, ostomy and continence RFP.
DHBs can continue to choose which continence products they purchase, including those from other suppliers. DHBs that choose to purchase SPQ’s products that are listed on the Pharmaceutical Schedule must do so under the terms and conditions, and at the prices, included in the agreement, from 1 May 2019.
PHARMAC expects to reach agreements with a number of other suppliers over the coming months, for the supply of urology, ostomy and continence products to DHBs.
Our response to what you told us
We appreciate the time people took to consider this consultation.
PHARMAC received one consultation response by 22 March 2019, advising that no technical or resource impacts are expected as a result of the proposal. This feedback was considered in making the decision to approve the agreement.
If you have any questions about this decision, you can email us at email@example.com; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.